Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product

Rhea-AI Summary

Accuray (NASDAQ: ARAY) announced a significant milestone as Shandong Cancer Hospital and Institute completed treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture. The hospital, which was the first in China to receive the system, can now treat an average of 95 patient treatment fractions daily.

This achievement is particularly significant given China's projected increase in cancer cases, with expectations of 7.1 million diagnoses by 2045, up from 4.8 million in 2022 - a 47% increase. The Tomo C System, based on the helical TomoTherapy® platform, is designed to provide ultra-precise treatments while enabling higher patient throughput, addressing the growing needs of China's underserved radiation therapy market.

Positive

• First successful implementation of Tomo C System in China with 100 patients treated
• System achieves high efficiency with 95 patient treatment fractions per day
• Strategic expansion into China's growing cancer treatment market (47% growth expected by 2045)
• Successful joint venture product deployment with CNNC

Negative

• None.

News Market Reaction

+0.44%

1 alert

+0.44% News Effect

On the day this news was published, ARAY gained 0.44%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MADISON, Wis., Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo^® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture. Shandong Cancer Hospital and Institute was the first hospital in China to receive the new Tomo C System which has already demonstrated its value by expanding clinical capabilities and the opportunity to offer potentially curative treatment to more people diagnosed with cancer. This first cohort of Tomo C System treatments also represent a milestone for Accuray which is focused on addressing the broad needs of the underserved Chinese radiation therapy market.

The number of new cancer cases in China is anticipated to increase by almost 47 percent in the coming years with about 7.1 million people expected to be diagnosed in 2045, compared to an estimated 4.8 million people in 2022¹. The data reinforces the importance of advanced radiotherapy technology that enables the precise treatment of the full spectrum of cancer cases clinical teams see in their practice.

"We are proud to support the Shandong Cancer Hospital and Institute team as they enhance their cancer treatment options with the new Tomo C System. I am pleased that a wide range of cancer types were successfully treated among these 100 patients and that the fast speed of treatment is expected to meaningfully increase capacity - enabling them to treat more patients per day," said Suzanne Winter, president and CEO of Accuray.

Continued Ms. Winter, "The system was developed to enable more clinicians in China to offer fast, effective, personalized cancer care to their patients. Its introduction expands our product portfolio in this important region and reinforces our commitment to providing our customers with the tools they need to offer the best care possible to any patient they believe would benefit from radiotherapy."

Shandong Cancer Hospital and Institute, founded in 1958, is a top center for cancer care, research, and prevention in China. Serving over 400,000 patients annually, it offers advanced treatments and collaborates with global leaders such as MD Anderson Cancer Center in the United States. The hospital is committed to innovation and excellence in cancer treatment.

"The introduction of the Tomo C Radiation Treatment Delivery System, based on the helical TomoTherapy^® platform, is a significant milestone in advancing precision radiotherapy for cancer patients," said Prof. Yu, President of Shandong Cancer Hospital. "The TomoTherapy platform has already demonstrated its transformative impact on cancer treatment. With the Tomo C System we can treat an average of 95 patient treatment fractions per day, enabling our team to provide innovative and effective care for more patients and reaffirming our commitment to the "Healthy China Initiative." This achievement sets a new benchmark for cancer care, propelling our efforts to the next level."

The Tomo C System is designed to provide medical care teams with greater certainty in the outcomes they achieve when treating patients with radiotherapy. Each component of the system – from helical imaging and delivery to advanced treatment planning and centralized data management – is designed to work seamlessly together to facilitate fast, ultra-precise treatments while enabling more patients to receive care each day.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations and goals regarding the company's products, services and innovations, including related to the Tomo C Radiation Treatment Delivery System; expectations regarding the company's joint venture in China; and patient experiences and patient outcomes. These risks and uncertainties include, but are not limited to, the effect of the current global economic environment, including in connection to the COVID-19 pandemic, on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands; reliance on third party collaborators, partnerships, strategic alliances and joint ventures; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 6, 2024, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com

________________________

¹International Agency for Research on Cancer, World Health Organization.
https://gco.iarc.fr/tomorrow/en/dataviz/tables?populations=160

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-first-100-patient-treatment-regimens-completed-in-china-using-the-tomo-c-radiation-treatment-delivery-system-a-cnnc-accuray-joint-venture-product-302355700.html

SOURCE Accuray Incorporated

FAQ

How many patients has the Tomo C System treated at Shandong Cancer Hospital?

The Tomo C System at Shandong Cancer Hospital has completed treatment for 100 patients, marking a significant milestone as the first installation in China.

What is the daily treatment capacity of ARAY's Tomo C System?

The Tomo C System can treat an average of 95 patient treatment fractions per day at Shandong Cancer Hospital.

What is the projected growth of cancer cases in China affecting ARAY's market?

Cancer cases in China are expected to increase by 47%, from 4.8 million in 2022 to approximately 7.1 million by 2045.

Which hospital first received ARAY's Tomo C System in China?

Shandong Cancer Hospital and Institute was the first hospital in China to receive the Tomo C System.